Sensei Biotherapeutics (NASDAQ:FTH) Stock Falls 7.8% – Time to Sell?

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) fell 7.8% during trading on Wednesday. The stock traded as low as $25.10 and last traded at $24.7830. 194,579 shares changed hands during trading, a decline of 19% from the average session volume of 239,758 shares. The stock had previously closed at $26.89.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on FTH. Guggenheim started coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, September 16th. They issued a “buy” rating and a $70.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Wall Street Zen lowered Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, September 26th. JonesTrading initiated coverage on Sensei Biotherapeutics in a report on Tuesday, August 4th. They set a “buy” rating and a $55.00 target price for the company. Finally, Citizens Jmp began coverage on Sensei Biotherapeutics in a research report on Monday, July 20th. They set an “outperform” rating and a $51.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.25.

Sensei Biotherapeutics Trading Up 1.7%

The firm’s 50-day moving average price is $31.85. The stock has a market cap of $673.00 million, a PE ratio of -0.18 and a beta of -0.29.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($5.04) by $2.20. As a group, analysts expect that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current year.

Hedge Funds Weigh In On Sensei Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vivo Capital LLC purchased a new stake in Sensei Biotherapeutics in the first quarter worth $22,758,000. Stempoint Capital LP purchased a new position in Sensei Biotherapeutics during the 1st quarter valued at $4,188,000. Alyeska Investment Group L.P. bought a new position in Sensei Biotherapeutics in the 2nd quarter worth $3,610,000. Bank of America Corp DE raised its holdings in Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Sensei Biotherapeutics by 178.2% in the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares during the period. Institutional investors own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing cancer immunotherapies designed to activate the immune system against tumors. The company’s approach is intended to address immune suppression within the tumor microenvironment and potentially improve patients’ responses to existing cancer treatments.

Sensei’s pipeline has included antibody-based and vaccine-based immunotherapies. Its lead programs have included SNS-101, an antibody designed to target the VISTA immune checkpoint, and earlier ImmunoPhage-based programs intended to stimulate tumor-specific immune responses.